You can seek FDA approval to launch a generic drug before the expiration of ACTONEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTONEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTONEL:-

You can seek FDA approval to launch a generic drug before the expiration of ALLEGRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALLEGRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALLEGRA:-

You can seek FDA approval to launch a generic drug before the expiration of ALLEGRA ALLERGY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALLEGRA ALLERGY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALLEGRA ALLERGY:-

You can seek FDA approval to launch a generic drug before the expiration of ALLEGRA HIVES's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALLEGRA HIVES's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALLEGRA HIVES:-

You can seek FDA approval to launch a generic drug before the expiration of ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION:-

You can seek FDA approval to launch a generic drug before the expiration of ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION:-

You can seek FDA approval to launch a generic drug before the expiration of ATELVIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATELVIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATELVIA:-

You can seek FDA approval to launch a generic drug before the expiration of ATRIPLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATRIPLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATRIPLA:-

You can seek FDA approval to launch a generic drug before the expiration of AVODART's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVODART's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVODART:-

You can seek FDA approval to launch a generic drug before the expiration of CANCIDAS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CANCIDAS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CANCIDAS:-

You can seek FDA approval to launch a generic drug before the expiration of CELEBREX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CELEBREX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CELEBREX:-

You can seek FDA approval to launch a generic drug before the expiration of CHILDREN'S ALLEGRA ALLERGY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CHILDREN'S ALLEGRA ALLERGY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CHILDREN'S ALLEGRA ALLERGY:-

You can seek FDA approval to launch a generic drug before the expiration of CHILDREN'S ALLEGRA HIVES's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CHILDREN'S ALLEGRA HIVES's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CHILDREN'S ALLEGRA HIVES:-

You can seek FDA approval to launch a generic drug before the expiration of COMTAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMTAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMTAN:-

You can seek FDA approval to launch a generic drug before the expiration of CYMBALTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CYMBALTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CYMBALTA:-

You can seek FDA approval to launch a generic drug before the expiration of EDARBI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EDARBI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EDARBI:-

You can seek FDA approval to launch a generic drug before the expiration of EDARBYCLOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EDARBYCLOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EDARBYCLOR:-

You can seek FDA approval to launch a generic drug before the expiration of ELOXATIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ELOXATIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ELOXATIN:-

You can seek FDA approval to launch a generic drug before the expiration of ENTEREG's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ENTEREG's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ENTEREG:-

You can seek FDA approval to launch a generic drug before the expiration of INVANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INVANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INVANZ:-

You can seek FDA approval to launch a generic drug before the expiration of INVEGA SUSTENNA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INVEGA SUSTENNA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INVEGA SUSTENNA:-

You can seek FDA approval to launch a generic drug before the expiration of ISTODAX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ISTODAX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ISTODAX:-

You can seek FDA approval to launch a generic drug before the expiration of JALYN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JALYN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JALYN:-

You can seek FDA approval to launch a generic drug before the expiration of KALETRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KALETRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KALETRA:-

You can seek FDA approval to launch a generic drug before the expiration of LOTRONEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOTRONEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOTRONEX:-

You can seek FDA approval to launch a generic drug before the expiration of LOVAZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOVAZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOVAZA:-

You can seek FDA approval to launch a generic drug before the expiration of NORVIR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NORVIR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NORVIR:-

You can seek FDA approval to launch a generic drug before the expiration of PRECEDEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRECEDEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRECEDEX:-

You can seek FDA approval to launch a generic drug before the expiration of SAMSCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAMSCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAMSCA:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 100's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 100's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 100:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 125's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 125's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 125:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 150's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 150's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 150:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 200's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 200's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 200:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 50's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 50's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 50:-

You can seek FDA approval to launch a generic drug before the expiration of STALEVO 75's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STALEVO 75's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STALEVO 75:-

You can seek FDA approval to launch a generic drug before the expiration of SUSTIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SUSTIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SUSTIVA:-

You can seek FDA approval to launch a generic drug before the expiration of TEMODAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TEMODAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TEMODAR:-

You can seek FDA approval to launch a generic drug before the expiration of VIOXX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIOXX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIOXX:-

You can seek FDA approval to launch a generic drug before the expiration of XELODA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELODA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELODA:-

You can seek FDA approval to launch a generic drug before the expiration of ZEMPLAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZEMPLAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZEMPLAR:-